Registry for tracking myasthenia gravis patients
Vitaccess Real MG Registry: A Prospective International Observational Patient Registry in Myasthenia Gravis Linking Clinical and Patient-reported Data.
This study is tracking the experiences of myasthenia gravis patients over 10 years to see how their treatment and symptoms affect their daily lives and well-being.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Vitaccess Ltd Industry-sponsored |
| Locations | 8 sites (Orange, California and 7 other locations) |
| Trial ID | NCT06064461 on ClinicalTrials.gov |
What this trial studies
The Vitaccess Real MG Registry is an observational patient registry aimed at collecting longitudinal data on myasthenia gravis (MG) patients, focusing on their treatment, symptoms, daily activities, and quality of life over a 10-year period. Approximately 600 patients will be recruited from the US and Europe, utilizing both traditional clinical site recruitment and community neurologist outreach in the US. Data will be gathered through a digital platform, allowing for patient-reported outcomes and clinical data integration from medical records. This comprehensive approach aims to enhance understanding of MG's impact on patients' lives.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a clinically-confirmed diagnosis of myasthenia gravis who reside in participating countries.
Not a fit: Patients currently participating in another clinical trial may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into the long-term effects of myasthenia gravis and improve patient care and treatment strategies.
How similar studies have performed: While observational registries are common, this specific approach to capturing longitudinal data on myasthenia gravis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (age ≥18 years) with a clinically-confirmed diagnosis of myasthenia gravis (MG). * Resident in one of the scope countries. * Access to a smartphone/tablet/computer/laptop * Willing and able to provide informed consent in their local language to take part in the study. Exclusion Criteria: * Participation in a clinical trial at the time of study enrolment.
Where this trial is running
Orange, California and 7 other locations
- UCI Health — Orange, California, United States (Recruiting)
- HSHS St. Elizabeth's Hospital — O'Fallon, Illinois, United States (Recruiting)
- UK HealthCare - University of Kentucky — Lexington, Kentucky, United States (Recruiting)
- Neurology Associates of South Jersey — Lumberton, New Jersey, United States (Recruiting)
- Medical University South Carolina — Charleston, South Carolina, United States (Recruiting)
- University of Texas Health Science Center at Houston — Houston, Texas, United States (Recruiting)
- Vitaccess Ltd — London, London, United Kingdom (Recruiting)
- University Hospitals Birmingham — Birmingham, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Mark JW Larkin, PhD — Vitaccess Ltd
- Study coordinator: Mark JW Larkin, PhD
- Email: mark.larkin@vitaccess.com
- Phone: +44 1865818983
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.